Mathematics · Geometry and Topology
Dysregulation of mTOR activity through LKB1 inactivation Review Chinese Journal of Cancer
Wei Zhou, Adam I. Marcus, Paula M. Vertino
See on the mapAbstract
Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either due to the genetic activation of its upstream activating signaling pathways or the genetic inactivation of its negative regulators. The tumor suppressor liver kinase B1 (LKB1), also known as serine/threonine kinase 11 (STK11), is involved in cell polarity, cell detachment and adhesion, tumor metastasis, and energetic stress response. A key role of LKB1 is to negatively regulate the activity of mTOR complex 1 (mTORC1). This review summarizes the molecular basis of this negative interaction and recent research progress in this area. Key words Energetic stress, metabolism, bi-allelic inactivation, protein translation www.cjcsysu.com Chinese Anti-Cancer AssociationCACA 427 Pharmaceutic reagents that specifically target mammalian target of rapamycin (mTOR) have been approved by the Food and Drug Administration (FDA) of the United States for treating advanced renal cancer, progressive or metastatic pancreatic cancer, and breast cancer in post-menopausal women with estrogen receptor (ER)- or progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative lesions. mTOR is aberrantly activated through either the activation of phosphatidylinositide 3-kinases (PI3K)/AKT signaling or the inactivation of LKB1/AMPK/ TSC signaling. Here, we focus on the activation of mTOR through the inactivation of LKB1 signaling. LKB1 as a Serine/Threonine Kinase The liver kinase B1 (LKB1) gene is located on chromosome